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Abstract
Background: The imbalance between extra cellular matrix (ECM) synthesis and degradation is critical aspect of various
hepatic pathologies including alcohol induced liver fibrosis. This study was carried out to investigate the effect of
acetaldehyde on expression of an extra cellular matrix degrading protease cathepsin L (CTSL) in HepG2 cells.
Methodology and Results: We measured the enzymatic activity, protein and, mRNA levels of CTSL in acetaldehyde treated
and untreated cells. The binding of CAAT enhancer binding protein a (C/EBP a) to CTSL promoter and its key role in the
transcription from this promoter and conferring responsiveness to acetaldehyde was established by site directed
mutagenesis, electrophoretic mobility shift assay (EMSA), chromatin immunoprecipitation (ChIP) assays and siRNA
technology. Acetaldehyde treatment significantly decreased CTSL activity and protein levels in HepG2 cells. A similar
decrease in the mRNA levels and promoter activity was also observed. This decrease by acetaldehyde was attributed to the
fall in the liver enriched transcription factor C/EBP a levels and it’s binding to the CTSL promoter. Mutagenesis of C/EBP a
binding motifs revealed the key role of this factor in CTSL transcription as well as conferring responsiveness to
acetaldehyde. The siRNA mediated silencing of the C/EBP a expression mimicked the effect of acetaldehyde on CTSL levels
and its promoter activity. It also abolished the responsiveness of this promoter to acetaldehyde.
Conclusion: Acetaldehyde down regulates the C/EBP a mediated CTSL expression in hepatic cell lines. The decreased
expression of CTSL may at least in part contribute to ECM deposition in liver which is a hallmark of alcoholic liver fibrosis.
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Introduction
Alcohol induced hepatic fibrosis is preceded by the
accumulation of ECM proteins in the liver. The accumulation
of these proteins which are predominantly synthesized by the
activated hepatic stellate cells is governed by the rate of their
synthesis and degradation. A battery of proteases has been
implicated in the degradation of these proteins. [1–3]. Many of
these proteases are synthesized and secreted by both stellate
cells and hepatocytes [4–6]. While the effect of alcohol or its
oxidative metabolite acetaldehyde on the levels of various
ECM degrading enzymes except CTSL have been extensively
studied in stellate cells [7]. Very few studies on the effect of this
metabolite on these enzymes have been carried out in
hepatocytes [8].
CTSL, a lysosomal cysteine protease expressed by almost all
types of eukaryotic cells is primarily involved in turnover and
degradation of intracellular proteins [9,10]. Over expression of this
protease has been reported in a variety of human tumors and by
malignantly transformed cultured cells [11,12]. In cultured cells,
after synthesis most of this protease is secreted in the medium. An
intact carboxy terminal is essential for this process [13]. Secreted
protease plays a key role in the invasion and metastasis of tumor
cells due to its ability to degrade ECM over a wide range of pH
[14,15]. However, normal hepatocytes also synthesize and secrete
large amounts of CTSL [16]. The secreted CTSL may play an
important role in the homeostasis of ECM which is deposited in
the fibrotic liver. However, no study delineating the role of
acetaldehyde, an oxidative metabolite of ethanol in regulation of
CTSL expression has been carried out in any cell type.
Interestingly, Mantle et al [17], observed a complete loss of
CTSL activity after in vitro treatment of human liver, brain and
muscle tissues by acetaldehyde. These authors ruled out the role of
direct inhibition of this protease by acetaldehyde but could not
elucidate the molecular mechanism for the observed loss in
enzymatic activity. Therefore, present study was planned to
investigate the effect of acetaldehyde on the expression of CTSL, a
potent ECM degrading protease and elucidate the molecular
mechanism.
Our results demonstrate, for the first time transcriptional down
regulation of CTSL expression in acetaldehyde treated HepG2
cells. The observed decrease in the expression of this protease
which is mediated by the liver enriched transcription factor C/
EBPa, may contribute at least in part to the accumulation of ECM
proteins in alcoholics.
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Reagents
Cbz-Phe-Arg-N-Methylcoumarin, cathepsin B inhibitor CA-
074, Acetaldehyde, CTSL and a -tubulin antibodies were
purchased from Sigma-Aldrich, St Louis, USA. The antibodies
for C/EBP a lamin B, HRP-labeled and alkaline phosphatase-
labeled mouse anti rabbit IgG were from Santa Cruz, CA, USA.
Polyclonal antibodies for C/EBPb and C/EBPd were purchased
from Abcam, Cambridge, UK. [c -
32P] ATP (3000 Ci/mmole)
was procured from Board of Radiation and Isotope Technology,
Jonaki, Hyderabad, India.`
Cell culture and acetaldehyde treatment
HepG2 (Human hepatocellular carcinoma) cells were cultured
as described earlier Arora and, Chauhan, [18]. Human hepatic
stellate cells were obtained from Amal K. Santra, Centre for Liver
Research, School of Digestive & Liver Diseases, Institute of Post
Graduate Medical Education & Research, Kolkata, India and
grown in DMEM F12-Ham media (Sigma – Aldrich, India)
supplemented with 10% FBS (Gibco-BRL, Gaithusberg,MD,
USA) and 20 ug/mL of Ciprofloxin. Acetaldehyde from a freshly
prepared stock in PBS (300 mM/L) was added to the cells cultured
in 25 Cm flask to a final concentration of 5 mM/L. After purging
with 5% CO2 the flasks were capped tightly and wrapped in
parafillm to prevent evaporation of acetaldehyde and incubated at
37uC for 24 hours. Growth rates of HepG2 cells in the presence
and absence of acetaldehyde were assayed as described in by Xia
et al. [19]
Enzyme assay
Cells were washed twice with ice cold PBS and lysed in Tris
HCl buffer (50 mM Tris HCl, pH 6.8; 150 mM NaCl; 10%
Glycerol; 1% Nonidet P-40) followed by two freeze thaw cycles.
The cell lysate was centrifuged at 10,000 g for 15 minutes at 4uC
to remove the cell debris. The human CTSL (hCTSL) activity in
the clear supernatant was assayed using a synthetic fluorogenic
substrate, CBZ-Phe-Arg-N-Methylcoumarin in the presence of a
specific cathepsin B inhibitor (CA-047) as described earlier [20].
Western blotting
HepG2 cells were washed twice with ice cold PBS and lysed in
250 ml of RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1%
Nonidet P-40, 2 mM PMSF, 2.0 mM EDTA, 10.0 mM MgCl2)
containing protease inhibitor cocktail (5 mg/ml) (Sigma, St Louis,
MO, USA). The total proteins (50 mg) were resolved on SDS-
PAGE (12%) and transferred on to a nitrocellulose membrane
(Millipore, Bedford, MA). This membrane was incubated with 5%
non fat dry milk powder in TBS (10 mM Tris–HCl, pH 7.4,
150 mM NaCl, 0.05% Tween-20) for 5.0 hours at room
temperature to block the nonspecific binding. Then it was
incubated with the primary antibody diluted in 1% non fat dry
milk powder at 4uC overnight. Next day, immunoreactive proteins
were detected with alkaline phosphatase conjugated or HRP
conjugated secondary antibody using BCIP NBT substrate
(Sigma-Aldrich, St Louis, USA) or Super Signal kits (Pierce
Biotechnology, Rockford, IL) respectively as substrates according
to the manufacturer’s instructions.
RNA isolation and Real time PCR
Total cellular RNA was isolated from the cultured cells was
isolated using Trizole tri reagent (Sigma-Aldrich St Louis, MO,
USA) according to the manufacturer’s instructions. The integrity
of the isolated RNA was checked on formaldehyde agarose gel.
Real time PCR as described by Keerthivasan et al [20], was
employed for the quantiation of CTSL, cathepsin B and cystatin C
mRNA levels. The message levels have been expressed as a ratio of
Ct values for these genes to 18S Ct values. The Ct values were
averages from triplicate PCR reaction for each sample.
Deletion analysis of C/EBP a binding motifs
The construction of various promoter reporter constructs used
in the present study has been described in our earlier study [21].
We used the same PCR based strategy to sequentially delete the
C/EBP a binding motifs from the hCTSL promoter. The
nucleotide sequences of these primers used for making promoter
–reporter construct containing one (pRB-7.5) and two (pRB-8.0)
C/EBP a binding motifs are given in table-1.
Mutagenesis of the C/EBPa binding motifs in hCTSL
promoter
The C/EBPa binding motifs at 21112/21126 (TTTTTATG-
TAATAA) and 21044/21058 (TAATTACATAAATT) positions
of hCTSL promoter were mutated to TTTTTtctTAATAA and
TAATTAagaAAATT respectively. The mutated nucleotides
have been shown in lower case. The mutagenesis was essentially
carried out as described by Antona et al [22] 2003. The primers
used are given in table-1.
Cell transfections and luciferase assay
HepG2 cells (1610
5) were seeded in each well of a six well plate
one day prior to the transfection. Next day cells were washed with
cold serum free DMEM and transfected with 1.0 mg of the
promoter reporter construct and 25 ng of pRL null vector
(Promega, Madison, WI, USA) using Transfast
TM(Promega)ac-
cording to manufacturers protocol.12.00 hours after transfection
the cells were harvested and processed for luciferase assay as
described earlier [20]. The luciferase activity was expressed as
LU/s.
Nuclear extract preparation
Cells were washed twice with ice cold PBS and collected in a
15 ml polypropylene tube with a rubber policeman and gently
pelleted. Then cells in the pellet were lysed in sucrose buffer
(Sucrose 0.32 M, Tris-HCl 10.0 mM (pH 8.0), MgCl2 3.0 mM,
Magnesium-acetate 2 mM, EDTA 0.1 mM and NP-40 0.5%) and
centrifuged at 5006g for 5 minutes. The nuclear pellet was again
washed with sucrose buffer without NP-40 and resuspended in low
salt buffer (HEPES 20 mM (pH 7.4), Mgcl21.5 mM, KCl 20 mM,
EDTA 0.2 mM 25% glycerol and 5 ul protease inhibitor/ml
(Sigma). The nuclear suspension was mixed with an equal volume
of high salt buffer (20 mM HEPES pH 7.4, 1.5 mM Mgcl2,
800 mM KCl, 0.2 mM EDTA 25% glycerol and 5 ml/ml protease
inhibitor) the nuclear suspension was incubated on ice for
45 minutes to release the nuclear proteins. The soluble nuclear
proteins were separated from the insoluble nuclear fraction by
centrifugation at 14006g for 5 minutes. After assaying total
proteins by BCA kit (Pierce Thermo Scientific) the soluble nuclear
fraction was stored at 280uC in small aliquots till further used.
Electrophoretic mobility shift assay
Complementary oligonucleotides (sequences given in table-1)
encompassing (21112/21126) or (21044/21058) C/EBPa
binding motifs of hCTSL promoter were annealed and end
labeled with c
32P-ATP using T-4 polynucleotide kinase (New
England Biolabs,) according to manufacturers instructions. The
free radioactivity from the radiolabeled DNA fragments was
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Oligonucleotides Sequence
Cathepsin L Sense: 59-GACTCTGAGGAATCCTATCCA-39 180 bp amplicon
Antisense: 59-AAGGACTCATGACCTGCATCAA-39
Cathepsin B Sense: 59-TGTAATGGTGGCTATCCTGCT-39 180 bp amplicon
Antisense: 59-AGGCTCACAGATCTTGCTACA-39
Cystatin-C Sense: 59-CAGCAACGACATGTACCACAG-39 180 bp amplicon
Antisense: 59-TTCCTTTTCAGATGTGGCTGGT-39
EMSA oligos C/EBP.1 WT Sense: 59- TTTTTATGTAATAA -39
C/EBP. 1 WT Antisense: 59- TTATTACATAAAAA -39
C/EBP.2 WT Sense: 59-TAATTACATAAATT-39
C/EBP. 2 WT Antisense: 5-9AATTTATGTAATTA-39
C/EBP.1 MT Sense: 59- TTTTTtctTAATAA -39
C/EBP.1 MT Antisense: 59- TTATTAagaAAAAA -39
C/EBP.2 MT Sense: 59- TAATTAagaAAATT-39
C/EBP.1 MT Antisense: 5-9AATTTATtctATTA-39
ChIP primers Flanking
the region of cathepsin L
promoter containing
C/EBP alpha motifs
Sense: CF 59-TGGGGTAAAGGCAGAGGTAA-39 198 bp amplicon
of mRNA
Antisense: CR 59-TGGAGAAATGTTGTAAGAGGAAA-39
C/EBPa siRNA 1
sequences cloned in
pSilencer 1.U6 siRNA
expression vector having
Apa I and Eco
RI flanking sites
Sense1: 59-TCTAGTATTTAGGATAACTTCAAGAGAGTTATCCTAAATACTA G AGTTTTTG-39 Target region
1378–1392 of
mRNA
Antisense 1: 59-AATTCAAAAACTCTAGTATTTAGGATAA CTCTCTTGAAGTTATCCTAAATACTAGAGGGCC-3 Apa I and Eco RI
adaptor
sequences have
been shown in
bold face
C/EBPa siRNA 1
sequences cloned in
pSilencer 1.U6 siRNA
expression vector having
Apa I and Eco
RI flanking sites
Sense 2: 59-CGGTTGTTCCCCTAGTTCTATTCAAGAGATA GAACTAGGGGAACAACCTTTTTG-39 Target region
1621–1639 of
mRNA
Antisense 2: 59-AATTCAAAAAGGTTGTTCCCCTAGTTCT ATCTCTTGAATAGAACTAGGGGAACAACCGGGCC-39 Apa I and Eco RI
adaptor
sequences have
been shown in
bold face
Scrambled siRNA
sequences cloned in
pSilencer 1.U6 siRNA
expression vector having
Apa I and Eco
RI flanking sites
Sense: 59-CTTAAGTCATAGCTATTGAATTCAAGAGAT TCAATAGCTATGACTTAAG-39
Antisense: 59-AATTCTTAAGTCATAGCTATTGAATCTC TTGAATTCAATAGCTATGACTTAAGGGCC-39 Apa I and Eco RI
adaptor
sequences have
been shown in
bold face
Oligos used for
deletion construct
of CTSL promoter
pRB8 Sense: 5-GGTACCAAGGTTATGGGGTAAAGGCA GAGG-39 KpnI site (Bold
face)
pRB7.5 Sense: 59CGGGGTACCGAAATGACAAAAGTT TAGAATG-39
Antisense: 59-AATTAAGCTTTCCTGCTGCGGTCGTAGC TGC-39 HindIII site (Bold
face)
Oligos used for site
directed mutagenesis
pRB9 Sense: 59-AAGGTACCAGCCTGAACAACAGAGCC A-39
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EMSA. The EMSA was performed using Promega’s Gel Shift
Assay System according to manufacturer’s protocol. All the
binding reactions were carried out at room temperature for
20 min using 5.0 mg of HepG2 nuclear lysate and 5.0 pmol of
radiolabeled probe in buffer containing 2% glycerol, 0.5 mM
MgCl2, 0.25 mM EDTA, 0.25 mM DTT, 25 mM NaCl, 5 mM
Tris-HCL pH 7.5, 0.025 mg/ml poly (dI-dC)-(dI-dC). An excess
100 molar excess of unlabelled wild type or mutated probe was
added to the binding reactions for specific and non specific
competitive assays. For supershift assays 8.0 mg of the specific
antibody against C/EBPa was added to the binding reactions
followed by overnight incubation at 4uC. The protein-DNA
complexes were resolved on 6% non-denaturing PAGE in 0.56
TBE buffer and visualized by autoradiography.
Chromatin immunoprecipitation(ChIP)
ChIP assays were performed using Imprint
TM Chromatin
Immunoprecipitation Kit (Sigma-Aldrich, St. Louis, USA) accord-
ing to the manufacturer’s protocol. 2.0 mg of antibody, diluted in
the 100 ml antibody buffer was incubated for 90 mins in the strip
wells provided in the kit. Simultaneously, 1610
6 HepG2 cells were
treated with 1% formaldehyde for 10 min at 25uC to cross link the
existing DNA-protein complex(s). After treating with glycine
(125.00 mM) to quench crosslinking, the cells were processed for
the isolation of nuclei. The nuclear pellet was resuspended in the
shearing buffer provided in the kit and subjected to sonication
using a Misonix sonicator at a power setting of 1.5 and a 100%
duty cycle, the extracts were sonicated for three 10-s pulses, with
two minutes on ice in between pulses. The sheared chromatin was
separated from the cell debris by centrifugation at 14,000 rpm for
10 min at 4uC. The supernatant was incubated in the wells pre-
coated with the antibody for 90 mins. The immunoprecipitated
DNA was recovered and used as template for PCR using CF and
CR as sense and antisense primers complementary to the region
flanking the C/EBPa motifs on hCTSL promoter. The nucleotide
sequences of these primers are given in table-1. The products were
resolved on agarose gel, purified and sequenced. PCR was
performed with an aliquot of sheared chromatin DNA before
immuno-precipitation and served as input control.
Construction of C/EBPa si RNA expression vector
Ambion siRNA Target Finder, an online tool was used for
predicting the siRNA sequence against C/EBPa. The comple-
mentary oligonucletides containing the predicted siRNA sequenc-
es were annealed, phosphorylated and cloned in expression vector
pSilencer 1.-U6 (Ambion, Austin, TX, USA). In this way two
human CEBP a siRNA expression vectors namely pU6/C/EBPa
-1 and pU6/C/EBPa-2 were constructed. Similarly a scrambled
siRNA expression vector (pU6/SC) was also generated which
served as negative control. The sequences of oligonucleotides used
for construction of these vectors are given in table-1. To determine
their silencing efficiencies these vectors were transiently transfected
in HepG2 cells and the expression of C/EBPa was assessed by
Western blotting.
Statistical analysis
The results in the present were analyzed using paired two tailed
student’s-t test. p value of #0.05 was considered statistically
significant.
Results
Acetaldehyde treatment decreases CTSL expression in
HepG2 cells
In the present study we used 5.0 mM concentration of
acetaldehyde to study its effect on expression of CTSL. To assess
the toxicity of acetaldehyde at this concentration we compared the
growth rates of HepG2 cells in its presence and absence and the
results are presented in figure 1. As evident from these results
acetaldehyde treated and untreated cells exhibited similar growth
rates and thus ruled out any cytotoxic effect of acetaldehyde on
Oligonucleotides Sequence
C/EBP 1 Mut Antisense:59-GTCATTTCATTTTTTATTAagaAAAA ACATTCATTG-3
C/EBP 1 Mut Sense: 59-CTACAATGAATGTTTTTtctTAATAAAA AAT GAAATG-39
C/EBP 2 mut Sense: 59-ATCCTTAATTAagaAAATTAAT ATCTACA-39
C/EBP 2 mut Antisense: 59-GTAGATATTAATTTtctTAATTAAGGAT-39
RSBI Antisense: 59-AATTAAGCTTTCCTGCTGCGGTCGTAGCTGC-39
Mutated nucleotides are shown in lower case and bold face.
doi:10.1371/journal.pone.0020768.t001
Table 1.Cont.
Figure 1. Growth rates of HepG2 cells in the presence and
absence of acetaldehyde. 10
5 cells were plated in each well of a six
well plate and allowed to grow in the presence or absence of 5.0 mM
acetaldehyde. After various time points the cells were trypsinized and
counted. Values are mean 6SD of three independent experiments
performed in triplicate.
doi:10.1371/journal.pone.0020768.g001
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HepG2 cells with this non-cytotoxic concentration of acetaldehyde
lead to a significant reduction (p=0.01; 2.3 fold) in the activity of
CTSL assayed fluorimetrically using a synthetic substrate CBZ-
Phe-Arg-Nmec (Figure 2A). However, no significant difference in
the activity of cathepsin B was observed at this concentration of
acetaldehyde (Figure 2B). To ascertain that the observed decrease
in CTSL was not due the direct inhibition of the enzyme by
acetaldehyde we quantiated this protease by Western blotting and
a representative blot is presented in (Figure 2C). hCTSL is
synthesized as a 42 kDa pre-proenzyme which is processed to a
34 kDa proenzyme and ultimately to a 26 kDa enzymatically
active form. As evident from figure 1C all these forms were
detected by the antibody used in the present study. Densitometry
of these blots revealed a 2.5 fold reduction in all three forms of
CTSL (Figure 2D). Since there was no effect on the levels of a-
tubulin upon this treatment, we concluded that acetaldehyde
down regulates the expression of CTSL. Consistent with these
results we observed significantly lower levels of CTSL mRNA in
acetaldehyde treated cells (Figure 3A). However, this treatment did
not affect the levels of cathepsin B, cystatin C mRNA or 18S RNA
(Figure 3B, C and D). These results suggest that acetaldehyde
decrease CTSL expression either by decreasing its gene transcrip-
tion or mRNA stability.
Transcriptional down regulation of hCTSL expression by
acetaldehyde
In a previous study our laboratory cloned hCTSL promoter and
characterized it by making a series of promoter reporter constructs
[21]. We used these constructs to assess the role of transcription in
down regulation of CTSL by this oxidative metabolite of ethanol.
Initially for this purpose a hCTSL full length promoter reporter
construct (pRB1.75) was transiently transfected in HepG2 cells
and the activity of luciferase reporter gene was assayed after
treatment with acetaldehyde or vehicle solution (PBS). As shown in
Fig. 4A, compared to PBS, acetaldehyde treatment decreased
CTSL promoter activity by 7.0 fold, which was statistically
significant (p=0.02). However, acetaldehyde did not affect
luciferase activity when these cells were transfected with pGL-3C
(luciferase cloned under SV-40 promoter) vector. These results
convincingly established the specificity of acetaldehyde for hCTSL
promoter and the role of transcription in decreasing CTSL
expression by this metabolite of ethanol.
Figure 2. Reduction in the activity and levels of CTSL by acetaldehyde treatment in HepG2 cells. Cathepsin L+cathepsin B activity was
assayed in the cell lysates spectroflourimetrically as described in materials and methods. The specific activity of CTSL was measured by including a
specific cathepsin B inhibitor (CA-074) in the assay mixture and used to calculate cathepsin B activity, by subtracting it from the total enzymatic
activity of L+B. (A) Effect of acetaldehyde treatment on CTSL activity (B) Effect of acetaldehyde treatment on cathepsin B activity. Values are mean 6
S.D from at least three independent experiments performed in triplicate. Values significantly different from untreated controls have been marked by
*(P#0.05). (C) Effect of acetaldehyde treatment on CTSL levels. CTSL levels in acetaldehyde treated and untreated cells were detected by western
blotting using a monoclonal antibody. Simultaneously western blot for a Tubulin was performed. Representative blots are shown in figure. (D)
Densitometric quantitation of CTSL levels in acetaldehyde treated and untreated cells. The three specific bands of CTSL (42 kDa, 34 kDa and 26 kDa)
representing prepro, pro and mature forms of the protease were quantitated densitometrically and the values thus obtained for each form were
added. The values obtained for a-tubulin were used as an internal control for equal loading. Values are mean 6 S.D from three independent
experiments. Values significantly different from untreated controls have been marked by *(P#0.05).
doi:10.1371/journal.pone.0020768.g002
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hCTSL promoter by deletion analysis
In an effort to identify the transcription factor binding motif(s) in
hCTSL promoter which confer responsiveness to acetaldehyde we
transfected the above mentioned series of promoter reporter
deletion constructs in HepG2cells and assayed luciferase activity
after acetaldehyde treatment. As shown in Fig. 4B, cells transfected
with the reporter construct containing the entire 1.87 kb promoter
region exhibited a 7.0 fold decrease in luciferase activity upon
acetaldehyde treatment. As reported earlier [21], gradual deletion
of 1092 bp (pRB-1.75, pRB9, pRB8, pRB7.5 pRB7) from the
upstream end of hCTSL promoter resulted in a corresponding
decrease in the luciferase activity. However, HepG2 cells
transfected with all these constructs except pRB-7 exhibited
significant reduction in luciferase activity after acetaldehyde
treatment. Interestingly pRB-6, another promoter reporter
construct lacking 413 bp from the 59end of hCTSL promoter in
pRB-7 lead to an increase in the luciferase activity both in the
presence and absence of acetaldehyde. While Bakhshi et al [21],
attributed the increase in promoter activity due to the deletion of
this region to the presence of potentially negative regulatory
element(s) in the deleted bases, results of this study suggest the
presence of acetaldehyde response motif(s) in the promoter region
upstream to 2783 bp.
C/EBP-a motif(s) confer acetaldehyde responsiveness to
hCTSL promoter
In view of the results of the previous experiment we analyzed
the sequence of hCTSL promoter upstream to 2783 for the
presence of putative transcription factor binding motifs by an
online tool http://.motif.genome.jp. This analysis besides several
other transcription factor binding motifs reveled the presence of
three putative C/EBPa binding sites at 21112/21126; 21044/
21058. As deletion of the most upstream 21378/21392 C/EBPa
motif did not affect the promoter activity we explored the role of
the other two sites in conferring acetaldehyde responsiveness to
hCTSL promoter. For this purpose we mutated them sequentially
as well as simultaneously. As shown in Fig. 5 mutagenesis of these
two motifs (21112/21126; 21044/21058) resulted in a
significant decrease in (p=0.01; 5.2 fold) the promoter activity
and a total loss of responsiveness to acetaldehyde. A similarly
decrease in promoter activity and acetaldehyde responsiveness was
observed by mutagenesis of 21112/21126 motif alone. However
mutation of 21044/21058 motif significantly reduced (p=0.05)
Figure 3. Reduction of CTSL mRNA in acetaldehyde treated HepG2 cells. Total cellular RNA isolated from acetaldehyde treated or untreated
cells was reverse transcribed and subjected to real time PCR using sybergreen and gene specific primers for (A) CTSL (B) cathepsin B or (C) cystatin C.
Similarly real time PCR for 18 S rRNA was performed and used as an internal control. Cycle threshold (Ct) values were calculated for each PCR and
relative fold change was calculated using 22
DD Ct method. Each set of observation was compared to the other set using a paired two-tailed t-test,
assuming unequal variances among the sample means. A p value of #0.05 was considered to be statistically significant. Values are mean 6 SD from
three independent experiments performed in triplicates. Values significantly different from control has been marked by *. (D) Analysis of PCR
products. After the completion of real time PCR amplified products were resolved on agarose gel to confirm the amplification of a single product.
Representative gel for each target is given in the figure.
doi:10.1371/journal.pone.0020768.g003
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acetaldehyde.
These results demonstrate that both C/EBPa binding motifs
(21112/21126; 21044/21058) are important for hCTSL
promoter activity but 21112/21126 motif is critical for its
responsiveness to acetaldehyde.
Binding of C/EBP a to its cognate motifs on hCTSL
promoter
EMSA were employed to assess the binding of C/EBPa to its
cognate motifs essential for hCTSL promoter activity and
conferring responsiveness to acetaldehyde. As shown in Fig. 6A
incubation of nuclear lysate isolated from HepG2 cells (without
Figure 4. Effect of acetaldehyde on CTSL promoter activity and identification of acetaldehyde response element. (A). CTSL promoter
activity in acetaldehyde treated and untreated cells. HepG2 cells were transfected with CTSL promoter reporter construct (pRB1.75) or pGL3C
(control) vector. After 24 hours the transfected cells were treated with 5.0 mM acetaldehyde or vehicle solution (PBS) for another 24 hours and then
the cells were lysed followed by assaying luciferase activity in the cell lysate. (B). Identification of acetaldehyde response elements in CTSL promoter
by deletion analysis. HepG2 cells transfected with various CTSL promoter reporter deletion constructs were cultured in the presence or absence of
acetaldehyde as described above and luciferase activity was assayed. All constructs were cotransfected with the pRLnull vector and the renilla
luciferase activity was used to normalize for the transfection efficiency. Each transfection was done in triplicates and results are expressed as mean 6
SD from three independent experiments. Values significantly different from control has been marked by *.
doi:10.1371/journal.pone.0020768.g004
Figure 5. Mutagenesis of C/EBP a binding motifs abolishes CTSL promoter activity and its responsiveness to acetaldehyde. The two
C/EBPa binding motifs were mutated individually or in combination and the resulting constructs were transfected in HepG2 cells. The mutated motifs
have been marked by X. The luciferase activity of these constructs was assayed after culturing the transfected cells in the presence or absence of
acetaldehyde for 24 hours. Values are mean 6 S.D from three independent experiments. Values significantly different from untreated controls have
been marked by *.
doi:10.1371/journal.pone.0020768.g005
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stranded radio-labeled DNA containing 21112/21126 or
21044/21058 C/EBP a binding motif suggesting the binding
of nuclear proteins to these DNA fragments. This interaction of
protein(s) to the radio-labeled probe was abolished by 100 molar
excess of the same un-labeled DNA fragment (wild type C/EBP a
motif) but not by the same unlabeled DNA containing mutated C/
EBPa binding motif. These results demonstrated the specific
binding of nuclear protein(s) to the CEBP a motif on radio-labeled
probe. A further retardation in the mobility of the above
mentioned protein - radio-labeled DNA complex by anti C/
EBPa antibody confirmed that the bound nuclear factor to the
radio-labeled probe was indeed C/EBPa.
However, no retardation in the mobility of the above mentioned
radio-labeled probe was observed when it was incubated with the
nuclear lysate isolated from acetaldehyde treated HepG2 cells. Thus
based on these results it was concluded that acetaldehyde treatment
abolished C/EBPa binding to its cognate motif on hCTSL promoter.
The in vivo binding of these motifs to the CEBP a was further
confirmed by ChIp assays (Figure 6B). For these assays chromatin
from the acetaldehyde treated and untreated HepG2 cells were
immuno-precipitated by anti C/EBPa antibody. This chromatin
was subjected to quantitative PCR using the primers flanking the
above mentioned C/EBPa binding motifs. The nucleotide sequence
of these primers is given in table-1. We observed amplification of the
right size DNA fragments using chromatin obtained from both
acetaldehyde treated and untreated cells. The identity of these
fragments were confirmed by double stranded DNA sequencing
(data not shown).however no DNA fragment of any size was
amplified when chromatin immuno precipated using the total rabbit
anti mouse IgG was used as template for PCR. Analysis of PCR
products on agarose gel also revealed strikingly higher amplification
of the target DNA fragment when chromatin immunoprecipitated
fromuntreated HepG2 cellswas used astemplatecompared towhen
it was immunoprecipitated from acetaldehyde treated cells. Whereas
input DNA from acetaldehyde treated and untreated cells exhibited
comparable amplification of the target fragments. These results
corroborated our EMSA results and confirmed that acetaldehyde
reduces the binding of C/EBPa to its cognate motifs on hCTSL
promoter. Interstingly, acetaldehyde reduced the C/EBPa expres-
sion without altering the levels of C/EBPd. However C/EBPb
expression was increased by acetaldehyde treatment (Fig. 6C). Since
hCTSL promoter contains two functional C/EBPa but no C/EBPb
or C/EBPd binding motifs, our results suggested that reduction in
C/EBPa levels in response to acetaldehyde treatment is responsible
for decreased CTSL expression in HepG2 cells.
Reduction in CTSL levels and its promoter activity by
siRNA mediated silencing of C/EBPa
Deletion analysis, site directed mutagenesis, EMSA and CHIP
assay established the specific binding of C/EBPa to its cognate
motifs on hCTSL promoter and its role in conferring acetaldehyde
responsiveness. To confirm that C/EBPa alone was sufficient to
mediate CTSL reduction by acetaldehyde we used C/EBPa
siRNA. As shown in Fig. 7A transfection of C/EBPa siRNA
expression vector decreased the expression of C/EBPa in HepG2
Figure 6. Acetaldehyde decrease/eliminates C/EBP alpha binding to CTSL promoter sequence. (A) Demonstration of specific binding of
C/EBP a to CTSL promoter. Radio-labeled double stranded DNA fragment (14 bp) encompassing wild type or mutated C/EBP a binding motif 1 or 2 (
described in figure - ) were incubated with the nuclear lysate (5 mg protein) prepared from acetaldehyde treated or untreated cells in the binding
assay buffer. The DNA protein complex were resolved on non denaturing 5% PAGE and detected by autoradiography. The binding reactions were
also carried out in the presence of 100 molar excess unlabelled double stranded DNA containing wild type or mutant C/EBP a binding motif to
ascertain the specificity of DNA protein interaction. In some of the reactions 10 mg of antibody against C/EBP a were incubated with or without
nuclear lysate before adding radio-labeled probe. Shift and supershift in the protein DNA complexes have been marked by S and SS respectively. (B)
In vivo binding of C/EBP-a to CTSL promoter. Crosslinked chromatin isolated from acetaldehyde treated or untreated HepG2 cells using C/EBP-a
antibody were subjected to PCR with gene specific primers (nucleotide sequence given in table) flanking the C/EBP-a binding motifs on CTSL
promoter. The amplified products were resolved on agarose gel. The cross linked chromatin immunoprecipitated with normal rabbit IgG were also
subjected to PCR using the same primers and served as negative control. Amplification of an expected 198 bp fragment is evident in all the lanes
except negative control. Input control is from non immunoprecipitated total genomic DNA. (C) Effect of acetaldehyde treatment on levels of C/EBP
transcription factors. Cell lysates of acetaldehyde treated or untreated cells were resolved on SDS-PAGE and subjected to western bloting using
specific antibodies for C/EBPa, C/EBPb or C/EBPd as described in Materials and Methods section. Simultaneously western blot for a-Tubulin was
performed and used for normalization for equal loading.
doi:10.1371/journal.pone.0020768.g006
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its level in acetaldehyde treated cells. However the expression of
this transcription factor remained unaltered by the scrambled
siRNA. Similarly the expression of lamin b and a-tubulin were not
affected by C/EBPa siRNA confirming its specificity against C/
EBPa alone. Consistent with the findings of mutagenesis
experiments, reduction in C/EBPa levels was accompanied by a
parallel decrease in the CTSL levels. Thus siRNA mediated
silencing of C/EBPa could mimic the effect of acetaldehyde on
CTSL expression in HepG2 cells. These results established beyond
doubt that reduction in C/EBPa alone was sufficient to down
regulate CTSL expression in these cells and thereby play a key role
in conferring acetaldehyde responsiveness to hCTSL promoter.
Finally we used siRNA mediated silencing to confirm that the
CEBP-a down regulation was sufficient to reduce CTSL promoter
activity. As evident from Fig. 7 B co-transfection of pRB-1.75 with
C/EBP-a siRNA expression vector in HepG-2 cells resulted in 80%
reduction (p=0.001) in hCTSL promoter activity. This reduction
was barely 24% when it was co-transfected with scrambled siRNA
vector. Acetaldehyde treatment could not cause any further
reduction in the C/EBPa siRNA mediated decrease of hCTSL
promoter activity. Whereas cells co-transfected with pRB-1.75 and
scrambled siRNA vector exhibited 81% reduction (p=0.03) in
luciferase activity upon acetaldehyde treatment compared to the
untreated control. Thus C/EBPa siRNA could decrease hCTSL
promoter activity to its level in acetaldehyde treated cells. These
results allowed us to conclude that silencing of C/EBPa alone is
sufficient for transcriptional down regulation of CTSL expression.
Reduction in CTSL and C/EBPa expression by
acetaldehyde treatment in human hepatic stellate cells
Our results convincingly demonstrated C/EBP a mediated
down regulation of CTSL by acetaldehyde in HepG2 cells. In view
of their being major fibrogenic cells we also investigated the effect
of acetaldehyde on the expression of CTSL and C/EBP isforms in
hepatic stellate cells. Treatment of these cells with acetaldehyde
(5 mM) did not exhibit any cytotoxic effect but resulted in a very
noticeable decrease in CTSL expression (Fig. 8). A parallel
reduction in the levels of C/EBPa was observed but no such
difference in the expression of C/EBP b, C/EBP d or a Tubulin
was apparent after acetaldehyde treatment (Fig. 8). This parallel
reduction in CTSL and C/EBPa expression by acetaldehyde
taken together with the results of the previous experiments
described in this study, suggest C/EBPa mediated down
regulation of CTSL levels in both HepG2 and hepatic stellate
cells with this metabolite of ethanol by a common mechanism.
Discussion
Acetaldehyde, an oxidative metabolite of ethanol produces
complex interplay of effects, including mitochondrial dysfunction,
autoimmune mediated cell injury, oxidative stress and overpro-
duction of inflammatory cytokines, which finally culminates in the
development of the alcoholic liver diseases [23–26]. Most of the
acetaldehyde induced liver injury occurs in the perivenous zone
around hepatocytes [27–29], followed by the accumulation of
ECM proteins such as collagens (type-1, III, IV, V and XVIII),
elastin, laminin and fibronectin etc [30]. Acetaldehyde induces the
synthesis of matrix proteins in hepatic stellate cells [31,32] and
inhibits hormone stimulated DNA synthesis in hepatocytes [33]. It
has also been reported to modulate the expression of extracellular
matrix degrading proteases like MMP-1, MMP-2 [7], uPA [34]
and MMP-9 [8,35] in human stellate cells and hepatocytes
respectively. Since no such information on ECM degrading
protease cathepsin L was available, primary objective of the
present study was to investigate the effect of acetaldehyde on
expression and activity of this protease.
Figure 7. Silencing of C/EBP a expression simulate the effect of acetaldehyde. (A). Simulation of the effect of acetaldehyde treatment on
CTSL expression by Silencing of C/EBP a expression. HepG2 cells transfected with 2.0 or 4.0 mg of C/EBP a si RNA expression vectors ( pU6-C/EBPa-
1+pU6-C/EBPa-2 ) or 4.0 mg of scrambled Si RNA expression vector(pU6-SC) were cultured in the presence or absence of 5 um acetaldehyde as
described in figure 3. After 24 hours the cells were lysed and levels of C/EBP a, CTSL, lamin B and a tubulin were detected by western blotting using
specific antibodies. The cell lysates prepared from untransfected, untreated or treated with acetaldehyde cells were also subjected to western
blotting using the above mentioned antibodies and served as control. Each blot shown is a representative of at least three separate experiments. (B).
Silencing of C/EBP a expression simulates the effect of acetaldehyde treatment on CTSL promoter activity. HepG2 cells co transfected with 1.0 mgo f
pRB-1.75 and 4.0 mg of C/EBP a si RNA expression vectors ( pU6-C/EBPa-1+pU6-C/EBPa-2 ) or scrambled Si RNA expression vector(pU6-SC) were
cultured in the presence or absence of 5 mM acetaldehyde as described in figure 3. After 24 hours the cells were lysed and luciferase activity was
assayed. Each transfection was done in triplicates and results are expressed as mean 6 SD from three independent experiments. Values significantly
different from control has been marked by *.
doi:10.1371/journal.pone.0020768.g007
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reactive CTSL in hepatocytes and hepatic stellate cells treateted
with noncytotoxic concentrations of acetaldehyde. Use of HepG2
cells to elucidate the molecular mechanism of this reduction
revealed a parallel decrease in the levels of transcription factor C/
EBPa and expression and promoter activity of this protease
suggesting it’s transcriptional down regulation by acetaldehyde.
Hepatic stellate cells after acetaldehyde treatment exhibited a
similar decrease in C/EBPa and CTSL levels. Consistent with our
findings Findik et al [36] also observed significant reduction in C/
EBPa protein in ethanol treated mouse liver and VL17 A cells. In
the present study we demonstrate that SiRNA mediated silencing
of C/EBPa can mimic the effect of acetaldehyde on CTSL
expression. Similarly mutagenesis of C/EBPa binding motifs can
abolish responsiveness of hCTSL promoter to acetaldehyde. These
results led to us to conclude the key role of C/EBPa in mediating
downregulation of CTSL expression by acetaldehyde. Similar
observations were made by Findik et al [36], in case of hepcidin
promoter in HepG2 cells.
Acetaldehyde induces collagen a1 (I) expression with the
involvement of C/EBP-b family of transcription factors with a
mechanism that requires H2O2 generation, an insight that directly
relates oxidative stress and acetaldehyde induced collagen
synthesis [37]. Similarly Attard et al, [38], observed increased
expression and promoter binding of C/EBP-b leading to
enhanced collagen a1 (I) synthesis in response to acetaldehyde.
In the present study HepG2 cells also exhibited increased
expression of C/EBPb after acetaldehyde treatment. However,
the expression of C/EBPd remained unaffected by this treatment.
Over expression of CTSL leads to its secretion in to the
extracellular milieu [13]. Also the localization of CTSL on the
hepatocytic villi is documented [39]. Since it is very potent in
degrading collagen, elastin, laminin, fibronectins and other
components of ECM CTSL present on hepatocytic membrane
and in neighboring milieu along with other proteases may be
expected to control the turnover of extra cellular matrix.
Interestingly, ethanol administration significantly decreased the
severity of destructive arthritis characterized by collagen degra-
dation in mice [40]. A specific ribozyme of CTSL exhibited a
similar reduction in the severity of destructive rheumatoid arthritis
thereby confirming the involvement of this protease in collagen
and proteoglycan degradation [41]. This is consistent with the
observation that blocking the secretion of CTSL can abolish
metastasis of melanoma cells, a process which requires ECM
degradation [14]. In view of these reports, results of the present
study, suggest that acetaldehyde mediated reduction in CTSL
expression may at least partly contribute to the accumulation of
matrix proteins in alcoholic liver fibrosis. Elevated expression of
matrix proteins in response to acetaldehyde by hepatic stellate cells
may further contribute to this process [31,32].
Pathological angiogenesis, irrespective of the etiology has been
extensively described in chronic liver diseases [42]. It is governed
by a delicate balance between pro and anti angiogenic factors.
Endostatin a very potent anti-angiogenic factor is generated from
collagen XVIII by secreted CTSL [43]. A decrease in the
synthesis, secretion and activity of CTSL will result in the
decreased endostatin production which in turn will favor
angiogenesis. Therefore, reduction in CTSL levels by acetalde-
hyde observed in the present study may explain the formation of
new vessels that are closely associated with the pattern of fibrosis
development typical of alcoholic liver disease [42]. However, the
role of decreased CTSL expression in inducing angiogenesis
during liver fibrosis is yet to be established experimentally.
In summary results of the present study demonstrate C/EBPa
mediated down regulation of the CTSL expression by acetalde-
hyde in HepG2 and hepatic stellate cells. This reduction in view of
its ability to efficiently degrade ECM proteins may at least partly
be responsible for shifting of balance of these proteins in favor of
their deposition in the liver.
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Figure 8. Acetaldehyde treatment decreases CTSL and C/EBP a
level in human hepatic stellate cells. Cell lysates of acetaldehyde
treated or untreated hepatic stellate cells were resolved on SDS-PAGE
and subjected to western bloting using specific antibodies for CTSL, C/
EBPa, C/EBPb or C/EBPd as described in Materials and Methods section.
Simultaneously western blot for a-Tubulin was performed and used for
normalization for equal loading.
doi:10.1371/journal.pone.0020768.g008
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